Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:58 AM
Ignite Modification Date:
2025-12-25 @ 12:58 AM
NCT ID:
NCT00002293
Eligibility Criteria:
Inclusion Criteria
Concurrent Medication:
Allowed:
* Experimental drugs (IND drugs) which are targeted specifically against the AIDS virus or which stimulate the immune system.
* Systemic or oral antibiotics.
Patients must have AIDS or AIDS-related syndromes (HIV infection:
* Group III or IV, CDC classification) and not have been treated for oral candidiasis during the past year.
* Patients can be entered into the study who have:
* Other oral lesions due to Kaposi's sarcoma, herpes zoster, and herpes simplex.
* A positive or negative oral culture for Candida.
* Must be able to follow instructions regarding the use of a pastille.
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
* Oral lesions diagnostic of oral candidiasis or systemic candidiasis.
* Suspected or proven candidal esophagitis.
Patients with the following are excluded:
* Oral lesions diagnostic of oral candidiasis or systemic candidiasis.
* Receiving any effective antifungal agent orally or intravenously within 72 hours of study entry.
* Not expected to survive for at least 6 months.
* Unable to voluntarily maintain a pastille in the buccal cavity for approximately 20 minutes twice a day.
* Known hypersensitivity to nystatin.
* Suspected or proven candidal esophagitis.
Prior Medication:
Excluded within 72 hours of study entry:
* Any oral or intravenous antifungal agent.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
12 Years
Study:
NCT00002293
Study Brief:
Protocol Section:
NCT00002293